Drugs / 2LXFS®
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT04308278 | Jan 2021 → Aug 2026 overdue | Epstein-Barr virus infection | Labo'Life | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 2LXFS | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04308278 ↗ |
| Route | Oral | “taking the content of one capsule a day” NCT04308278 ↗ |